NCT07095712已完成1 期
An Open-label Multicenter, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for Amyotrophic Lateral Sclerosis (ALS) Due to TARDBP (TDP-43) Genetic Mutation
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 1
- 试验地点
- 4
- 主要终点
- Clinical Functioning
研究概览
简要总结
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
详细描述
This is an interventional study to evaluate the safety and efficacy of treatment with an individualized antisense oligonucleotide (ASO) treatment in a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 49 Years 至 49 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s)
- •Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records
- •Genetically confirmed neurological disorder
排除标准
- •Participant has any condition that in the opinion of the Site Investigator would ultimately prevent the completion of study procedures
- •Use of an investigational medication within less than 5 half-lives of the drug at enrollment
研究组 & 干预措施
Open Label
Experimental
干预措施: nL-TARD-001 (Drug)
结局指标
主要结局
Clinical Functioning
时间窗: Baseline to 12 months
Change from baseline at 12-months post nL-TARD-001 administration in scores on Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R).
次要结局
- Disease Biomarkers(Baseline to 12 months)
- Safety and Tolerability(Baseline to 12 months)
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
Observational study on the effects of a training on the use of CardioplexolEUCTR2018-002311-10-DESwiss Cardio Technologies AG165
进行中（未招募）
1 期
A multi-center, open label, single group, observational study to investigate the effects of training on the administration of Cardioplexol (TM)?Medical conditions with the need for an elective surgical coronary artery bypass grafting (CABG) and/or a valve repair/replacement .EUCTR2018-002311-10-ATSwiss Cardio Technologies AG165
进行中（未招募）
1 期
Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)NCT06816498n-Lorem Foundation1
进行中（未招募）
不适用
Study to Evaluate BIIB019, Daclizumab High Yield Process (DAC HYP), when administered by Pre-filled SyringeEUCTR2010-023856-97-PLBiogen Idec Limited100
进行中（未招募）
不适用
Study to Evaluate BIIB019, Daclizumab High Yield Process (DAC HYP), when administered by Pre-filled SyringeEUCTR2010-023856-97-HUBiogen Idec Limited120